Completed PHASE2 INTERVENTIONAL 2-arm NCT03329443

The Effect of Spironolactone on Acute Kidney Injury in Patients Undergoing Coronary Angiography

Sponsor: Alhasan Mujtaba Abdul-Wahid

Conditions Acute Kidney Injury Contrast-induced Nephropathy IHD

Interventions Placebo Oral Tablet Spironolactone

Updated 7 times since 2018 Last updated: Sep 6, 2018 Started: Sep 1, 2017 Primary completion: Sep 1, 2018 Completion: Sep 4, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Acute Kidney Injury and Contrast-induced Nephropathy, this trial is completed. The trial is conducted by Alhasan Mujtaba Abdul-Wahid and has accumulated 7 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Oct 2018 — Jan 2021 [monthly]

Completed PHASE2

Status: Recruiting → Completed

▶ Show 2 earlier versions

Jun 2018 — Oct 2018 [monthly]

Recruiting PHASE2
Feb 2018 — Jun 2018 [monthly]

Recruiting PHASE2

First recorded

Sep 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Alhasan Mujtaba Abdul-Wahid
Ministry of Health-Basra Health Directorate-Al-Sader Teaching Hospital

Data source: University of Baghdad

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Basra, Iraq